Dr. Wyatt is an early career investigator with an academic focus on cancer genomics. He has a broad background in basic molecular biology and genetics, as well as considerable experience in cancer bioinformatics and the analysis of complex datasets. His primary research goals are to dissect the clinical relevance of genomic alterations in metastatic genitourinary cancers, and develop minimally-invasive biomarkers for guiding therapy selection. His laboratory leverages a variety of innovative next-generation sequencing techniques to interrogate tissue and liquid biopsies from patients enrolled on a series of ongoing clinical trials and protocols. The team works very closely with senior medical oncologists and urologists to enable patient-sample driven science.
In the past 18 months the Wyatt laboratory has published in Clinical Cancer Research, JAMA Oncology, European Urology, Journal of the National Cancer Institute, and Cancer Discovery. Together, their body of work has demonstrated that plasma circulating tumor DNA (ctDNA) can help predict resistance and guide therapy use in prostate and bladder cancers.
Dr. Wyatt’s research is funded through peer-reviewed grants from the NIH/NCI, CIHR (project grant and early career investigator award), Prostate Cancer Foundation, Prostate Cancer Canada, Canadian Cancer Trials Group, Bladder Cancer Canada, and several contract research agreements with industry.
Dr. Wyatt’s laboratory team is physically housed at the Vancouver Prostate Centre located on the VCH campus. The Vancouver Prostate Centre is part of the Department of Urologic Sciences (FoM, UBC), and part of VCHRI. Dr. Wyatt’s current laboratory team consists of 6 graduate students, 2 technicians, and 3 clinical-research fellows, as well as several undergraduate appointments.